Is Sunitinib an immune drug or a targeted drug?

Sunitinib (Sunitinib) is a targeted drug called a protein kinase inhibitor. It is a second-generation targeted drug and is not an immune drug. This is a treatment used to treat kidney cancer (advanced or metastatic) that has spread to other parts of the body, a rare type of sarcoma called gastrointestinal stromal tumor (GIST), and pancreatic neuroendocrine tumors (pNET). Protein kinase is a chemical messenger (a type of enzyme) that plays a role in the growth of cancer cells. Sunitinib blocks protein kinases. It can stop tumor growth or shrink tumors. Sunitinib usually comes in capsule form that can be swallowed whole once a day.